NBP — NovaBridge Biosciences

Nasdaq · Health Care · Pharmaceuticals · CIK 1778016 ·
Last close
$1.89
Market Cap
$218.58M
52W High
$2.27
52W Low
$1.46
ADV30
263,620
Next earnings
2026-08-20
NovaBridge Biosciences, a biotechnology company, engages in the research and development of immuno-oncology agents for the treatment of cancer in the United States. The company operates through two segments, Oncology and Ophthalmology. Its product pipeline comprises givastomig, a potential CLDN18.2 bispecific antibody, which is in phase 2 clinical trial combination with nivolumab and chemotherapy for the treatment of gastric cancer and other CLDN18.2-positive gastrointestinal malignancies; Phase 1b clinical trial in combination with nivolumab and chemotherapy in first-line gastric cancer. The company also develops VIS-101, VEGF-A × ANG-2 bispecific biologics in Phase 2 clinical trial to treat wet age-related macular degeneration and other retinal diseases, including diabetic macular edema; ragistomag, which is in Phase 1clinical trial for multiple solid tumors. It has a licensing agreement with AskGene to develop and commercialize VIS-101; collaborations with Bristol Myers Squibb for the development of givastomig; and license and collaboration agreement with AbbVie Ireland Unlimited Company for the development and commercialization of lemzoparlimab. The company was formerly known as I-Mab and change its name to NovaBridge Biosciences in October 2025. NovaBridge Biosciences was founded in 2014 and is headquartered in Rockville, Maryland.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Dec 2025 0 -72,900,000 -30,787,000 260,522,000 210,632,000 29,581,000
Sep 2025 0 -8,989,000 -6,828,000 277,410,000 228,064,000 18,495,000
Jun 2025 0 -7,114,000 -5,504,000 206,708,000 165,404,000 9,975,000
Mar 2025 0 -5,266,000 -3,150,000 208,941,000 53,597,000 10,600,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-23,706,000
Investing CF
$-109,000
Financing CF
$57,725,000
CapEx
$-38,000
Dividends Paid
Buybacks
$0
EPS Diluted TTM
$-0.12
As of
2026-08-09

Balance + Analyst (yfinance extras)

Retained Earnings
$-1,332,308,000
Inventory
Receivables
$1,793,000
ST Investments
$210,000
EBIT TTM
$-94,269,000
Pretax Income TTM
$-88,340,000
Interest Exp TTM
Analysts
3

Annual Trend (SEC EDGAR, last 5y)

Revenues vs Net Income (last 5y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 0 -94,269,000 -46,269,000 260,522,000 29,581,000 -20,597,000
Dec 2024 0 -51,426,000 -22,230,000 212,680,000 11,520,000 -52,669,000
Dec 2023 632,000 -48,976,000 -207,729,000 368,922,000 126,338,000 -72,697,000
Dec 2022 -1,551,000 -53,078,000 -371,053,000 590,446,132 168,678,417 -49,582,000
Dec 2021

TTM Snapshot

Revenues TTM
NetIncome TTM
OpCashFlow TTM
Assets (Latest)
Forward EPS
$-1.06

Max Pain — expiry 2026-09-18 (volume-derived — Yahoo OI feed degraded)

max pain strike: $2.50 · spot: $1.96 · call volume: 19 · put volume: 20
Expected Move to 2026-09-18: ±$0.65 (33.16%) — implied range $1.31$2.61 · ATM straddle on $2.50 strike

Peers — same industry

TickerNameMarket CapLastDaily %
BCYC BICYCLE THERAPEUTICS PLC $218.12M $4.33
PEPG PepGen Inc. $220.94M $3.19
NGEN NERVGEN PHARMA CORP. $215.05M $2.00
ORGO Organogenesis Holdings Inc. $214.89M $1.67
KROS Keros Therapeutics, Inc. $213.74M $10.78

News headlines (Yahoo Finance, 1h cache)

NovaBridge Biosciences (NBP) (H1 2026) Earnings Call Highlights: Strong Cash Position and ...
2026-08-20 21:02 · Yahoo
NovaBridge Biosciences Q2 2026 Earnings Call Summary
2026-08-20 12:30 · Yahoo
NovaBridge Reports First Half 2026 Financial Results and Highlights Pipeline Momentum and Strategic Execution
2026-08-20 11:00 · Yahoo
NovaBridge to Report First Half 2026 Financial Results and Provide a Corporate Update on Thursday, August 20, 2026
2026-08-13 21:00 · Yahoo
NovaBridge Biosciences to Hold Annual General Meeting on September 8, 2026
2026-07-24 21:00 · Yahoo
NovaBridge Biosciences Appoints Dr. Srishti Gupta as Chief Executive Officer
2026-06-29 11:00 · Yahoo
NovaBridge Biosciences Receives FDA Fast Track Designation for Givastomig in First-Line HER2-Negative Metastatic Gastric Cancer
2026-06-16 11:00 · Yahoo
Companies Like NovaBridge Biosciences (NASDAQ:NBP) Can Afford To Invest In Growth
2026-05-28 11:50 · Yahoo
NovaBridge to Present at the 2026 Jefferies Global Healthcare Conference
2026-05-28 11:00 · Yahoo
NovaBridge to Present at the H.C. Wainwright 4th Annual BioConnect Investor Conference
2026-05-12 11:00 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.